| Market Cap | ₹4,22,523 CrPharmaceuticals |
|---|---|
| TTM Net Profit | ₹12,096 CrUp 27% YoY (Qtr) |
| PE TTM | 34.93xSector PE 48.7x |
| Promoter Holding | 52.68%Latest Quarter |
Key highlights
- US FDA approves supplemental Biologics License Application for ILUMYA in active psoriatic arthritis
- Approval targets a patient population of approximately 2.4 million Americans living with the condition
- Clinical efficacy supported by Phase 3 INSPIRE-1 and INSPIRE-2 studies over a 52-week period
- Specialty medicines portfolio now accounts for approximately 20% of Sun Pharma total sales
- The drug remains the first biologic to earn the National Psoriasis Foundation Seal of Recognition
Expanding ILUMYA Utility in the United States Rheumatology Market
Sun Pharmaceutical Industries has reached a significant regulatory milestone with the US FDA approval of ILUMYA for active psoriatic arthritis. This condition, which causes joint pain and stiffness, affects roughly one-third of people living with psoriasis. The approval allows Sun Pharma to offer a healthcare provider-administered IL-23 inhibitor option for adults who may be unable to self-administer treatment.
This expansion leverages the established clinical footprint of ILUMYA in plaque psoriasis, where it has been marketed since 2018. The move strengthens Sun Pharma's high-growth Innovative Medicines portfolio, which is a critical driver for the company's global specialty strategy.
Phase 3 INSPIRE Clinical Trial Outcomes
- The approval is based on safety and efficacy data from the 52-week INSPIRE-1 and INSPIRE-2 studies
- Efficacy was evaluated after only two doses at the 24-week mark in adult patients
- Clinical data showed a safety profile consistent with the well-documented history of ILUMYA
- Adverse reactions in psoriatic arthritis trials included upper respiratory tract infections and COVID-19
- Clinical trials were conducted as global, multicenter, randomized, double-blind, placebo-controlled studies
Strategic Portfolio Expansion
FDA approval of ILUMYA for adults with active psoriatic arthritis represents another important innovative medicine milestone for Sun Pharma and builds on the established clinical experience of ILUMYA in plaque psoriasis. As an IL-23 inhibitor administered exclusively by a healthcare provider, ILUMYA is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care.
Financial Context and Regulatory Pipeline
The approval comes as Sun Pharma reports robust financial performance, with Q1 FY27 net profit reaching ₹2,894.79 crore, a 27% year-on-year increase. The company has been active in expanding its specialty pipeline throughout 2026, recently receiving approvals for generic semaglutide in Brazil, South Africa, and India. Sun Pharma's vertically integrated operations now deliver medicines to over 100 countries, supported by an R&D spend guided at 6% to 8% of sales.
To manage its capital structure, the company recently raised ₹7,816 crore through non-convertible debentures in October 2026 to refinance acquisition-related debt, maintaining a mid-range durability score of 55.
| Date | Announcement | Amount |
|---|---|---|
| 29 Jul 2026 | Received approval from Brazil's ANVISA to manufacture and market semaglutide in BrazilSource: BSE filing | – |
| 15 Jul 2026 | Received approval from South African Health Products Regulatory Authority (SAHPRA) to manufacture and market generic semaglutide in South AfricaSource: genohopebio.com | – |
| 22 Jan 2026 | Received approval from Drugs Controller General of India (DCGI) to manufacture and market generic semaglutide injection in IndiaSource: tradingview.com | – |
| 15 Dec 2025 | Received US FDA approval for supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) to treat nail plaque psoriasisSource: sunpharma.com | – |
| 26 Nov 2025 | Received US FDA label update approval for UNLOXCYT (cosibelimab-ipdl)Source: expresspharma.in | – |
| 30 Aug 2025 | Received approval from CDSCO Subject Expert Committee (SEC) for Phase IV clinical trial protocol of high-concentration formulationSource: trial.medpath.com | – |
What to watch next
- Q2 FY27 financial results announcement scheduled for 30 October 2026
- Commercial rollout of ILUMYA for the psoriatic arthritis indication in the U.S. market
- Further updates on the global rollout of semaglutide following recent international approvals
“Adding an IL-23 inhibitor option that is administered by a healthcare provider gives us a new way to offer appropriate patients additional support and engagement with their healthcare team.”
| Share price | ₹1761 |
|---|---|
| Market capitalisation | ₹4.23L Cr |
| Revenue (annual) | ₹58,462.04 Cr |
| Net profit (annual) | ₹11,479.42 Cr |
| Revenue (latest quarter) | ₹15,299.88 Cr+4.71% vs previous quarter |
| Net profit (latest quarter) | ₹2,894.79 Cr+6.66% vs previous quarter |
| P/E (TTM) | 34.93×Sector 48.73× |
| Promoter holding | 52.68%-1.80% QoQ |
| FII holding | 14.36%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Sun Pharmaceutical Industries Limited announcing the US FDA approval for its supplemental Biologics License Application for ILUMYA. Market figures from a third-party data provider.
